FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

hington, D.C. 20549	
	Į

	Washington, D.C. 20549	
STATEMENT OF (	CHANGES IN BENEF	FICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person VAN NOSTRAND ROBERT L					2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ ITCI ]								(Che	elationship eck all app X Direc	,	ng Pers	son(s) to Is 10% Ov		
(Last)	(Fi	rst) (f	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/31/2023									Office below	er (give title /)		Other (s below)	pecify	
C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable)  X Form filed by One Reporting Person					
(Street) NEW YO	Street) NEW YORK NY 10016			Dul	Form filed by More than One Reporting Person											orting			
(City)	(St	ate) (2	Zip)		$ _{\square}$	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								uction or writt	en plan	n that is inter	ided to		
		Table	I - No	n-Deriva	ative S	Secu	rities	Acq	uired,	, Dis	posed of	, or E	3ene	ficia	lly Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Date)			Exec		Deemed cution Date, ly nth/Day/Year)		Transaction Disposed (Code (Instr. 5)		es Acquired (A) Of (D) (Instr. 3, 4		A) or 3, 4 and	Securit Benefic Owned	Amount of ecurities eneficially		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or F	Price	Transa	Reported Transaction(s) (Instr. 3 and 4)		<u> </u>	(Instr. 4)
Common Stock 12/31/2				/2023				A		76	A	.   ;	\$71.62	2 9	9,611		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4)		(	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y [0	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amo or Num of Shar	ber					

**Explanation of Responses:** 

/s/ Lawrence J. Hineline, Attorney-in-fact

01/03/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).